Press Resease

Gene Therapy Market by Type (Somatic Cell Gene Therapy and Germ Cell Gene Therapy) and by Application (Genetic Disorders, Cancer, Cardiovascular Disease, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024

Published Date: 15-Jan-2019 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3218 Status : Published

Global gene therapy market expected to generate around USD 2,269 million by 2024, at a CAGR of around 19.42% between 2018 and 2024. The global gene therapy market is likely to be driven by the growing prevalence of life-threatening genetic disorders, such as sickle-cell anemia, cystic fibrosis, down syndrome, across the globe in the future.

Description

The report covers a forecast and an analysis of the gene therapy market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints of the gene therapy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the gene therapy market on a global and regional level.

In order to give the users of this report a comprehensive view of the gene therapy market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Gene Therapy Market

The report provides company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the gene therapy market by segmenting the market based on type, application, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. Based on the type, the gene therapy market is bifurcated into somatic cell gene therapy and germ cell gene therapy. Based on application, the gene therapy market is classified into genetic disorders, cancer, cardiovascular diseases, and others.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries including the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil.

Some key players of the gene therapy market include UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension Therapeutics, Voyager Therapeutics, Human Stem Cell Institute, Bristol Myer’s Squibb, and Chiesi Farmaceutici S.p.A., among others.

This report segments the global gene therapy market into:

Global Gene Therapy Market: By Type

  • Somatic Cell Gene Therapy
  • Germ Cell Gene Therapy

Global Gene Therapy Market: By Application

  • Genetic Disorders
  • Cancer
  • Cardiovascular Disease
  • Others

Global Gene Therapy Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global gene therapy market, 2017 - 2024 (USD Million)
    • 2.2. Global gene therapy market: Snapshot
  •  
  • Chapter 3. Gene Therapy Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global gene therapy market drivers: Impact analysis
      • 3.2.2. The increasing prevalence of genetic disorders and other lifestyle-related life-threatening diseases across the globe
      • 3.2.3. Rising need for gene therapy based targeted treatment
    • 3.3. Market Restraints
      • 3.3.1. Global Gene therapy market restraints: Impact analysis
      • 3.3.2. Need for an individual case-by-case approach
    • 3.4. Opportunities
      • 3.4.1. Increasing adoption of personalized medicines
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. The threat from new entrants
      • 3.5.4. The threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by type
      • 3.6.2. Market attractiveness analysis, by application
      • 3.6.3. Market attractiveness analysis, by region
  •  
  • Chapter 4. Global Gene Therapy Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global gene therapy market: company market share, 2017
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
      • 4.2.4. Research and Development and Regional Expansion
  •  
  • Chapter 5. Global Gene Therapy Market - Type Analysis
    • 5.1. Global gene therapy market: Type overview
      • 5.1.1. Global gene therapy market revenue share, by Type, 2017 and 2024
    • 5.2. Somatic cell gene therapy
      • 5.2.1. Global gene therapy market for Somatic cell gene therapy, 2017 - 2024 (USD Million)
    • 5.3. Germ cell gene therapy
      • 5.3.1. Global gene therapy market for Germ Cell Gene Therapy, 2017 - 2024 (USD Million)
  •  
  • Chapter 6. Global Gene Therapy Market - Application Analysis
    • 6.1. Global gene therapy market: Application overview
      • 6.1.1. Global gene therapy market revenue share, by Application, 2017 and 2024
    • 6.2. Genetic Disorders
      • 6.2.1. Global gene therapy market for genetic disorders, 2017 - 2024 (USD Million)
    • 6.3. Cancer
      • 6.3.1. Global gene therapy market for Cancer, 2017 - 2024 (USD Million)
    • 6.4. Cardiovascular Disease
      • 6.4.1. Global gene therapy market for Cardiovascular Disease, 2017 - 2024 (USD Million)
    • 6.5. Other Diseases
      • 6.5.1. Global gene therapy market for other diseases, 2017 - 2024 (USD Million)
  •  
  • Chapter 7. Global Gene Therapy Market - Regional Analysis
    • 7.1. Global gene therapy market: Regional overview
      • 7.1.1. Global gene therapy market revenue share, by region, 2017 and 2024
    • 7.2. North America
      • 7.2.1. North America gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.2.2. North America gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.2.3. The U.S.
        • 7.2.3.1. The U.S. gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.2.3.2. The U.S. gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.2.4. Canada
        • 7.2.4.1. Canada gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.2.4.2. Canada gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.2.5.2. Rest of North America gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3. Europe
      • 7.3.1. Europe gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.2. Europe gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.3.3. U.K.
        • 7.3.3.1. U.K. gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.3.3.2. U.K. gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.3.4. Germany
        • 7.3.4.1. Germany gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.3.4.2. Germany gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.3.5. France
        • 7.3.5.1. France gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.3.5.2. France gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.3.6. Italy
        • 7.3.6.1. Italy gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.3.6.2. Italy gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.3.7. Spain
        • 7.3.7.1. Spain gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.3.7.2. Spain gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.3.8. Russia
        • 7.3.8.1. Russia gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.3.8.2. Russia gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.3.9. Rest of Europe
        • 7.3.9.1. Rest of Europe gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.3.9.2. Rest of Europe gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.4.2. Asia Pacific gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.4.3. China
        • 7.4.3.1. China gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.4.3.2. China gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.4.4. Japan
        • 7.4.4.1. Japan gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.4.4.2. Japan gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.4.5. India
        • 7.4.5.1. India gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.4.5.2. India gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.4.6. Australia
        • 7.4.6.1. Australia gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.4.6.2. Australia gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.4.7.2. Rest of Asia Pacific gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America gene therapy market revenue, by type, 2017 - 2024(USD Million)
      • 7.5.2. Latin America gene therapy market revenue, by application, 2017 - 2024(USD Million)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.5.3.2. Brazil gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.5.4. Mexico
        • 7.5.4.1. Mexico gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.5.4.2. Mexico gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.5.5. Argentina
        • 7.5.5.1. Argentina gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.5.5.2. Argentina gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.5.6. Rest of Latin America
        • 7.5.6.1. Rest of Latin America gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.5.6.2. Rest of Latin America gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.6. The Middle East and Africa
      • 7.6.1. The Middle East and Africa gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.6.2. The Middle East and Africa gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.6.3. Saudi Arabia
        • 7.6.3.1. Saudi Arabia gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.6.3.2. Saudi Arabia gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.6.4. UAE
        • 7.6.4.1. UAE gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.6.4.2. UAE gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.6.5. South Africa
        • 7.6.5.1. South Africa gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.6.5.2. South Africa gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.6.6. Qatar
        • 7.6.6.1. Qatar gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.6.6.2. Qatar gene therapy market revenue, by application, 2017 - 2024 (USD Million)
      • 7.6.7. Rest of the Middle East and Africa
        • 7.6.7.1. Rest of the Middle East and Africa gene therapy market revenue, by type, 2017 - 2024 (USD Million)
        • 7.6.7.2. Rest of the Middle East and Africa gene therapy market revenue, by application, 2017 - 2024 (USD Million)
  •  
  • Chapter 8. Company Profile
    • 8.1. UniQure N.V
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Therapy portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Spark Therapeutics LLC
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Therapy portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. Bluebird Bio
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Therapy portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. Juno Therapeutics
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Therapy portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. GlaxoSmithKline
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Therapy portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Celgene Corporation
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Therapy portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Shire Plc
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Therapy portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Sangamo Biosciences
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Therapy portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments

Methodology

Free Analysis

Gene therapy is the process where a DNA is inserted into a patient to treat a specific disease. The DNA is carefully selected to correct the effect of a mutated gene. Gene therapy is suitable for treating cancer by destroying a certain group of cells. Gene therapy has the potential to eventually eliminate genetic defects, kill cancerous cells, and prevent cardiovascular diseases. A fundamental requirement for gene therapy is the correct identification of genes coding for diseases.

As per the World Health Organization, there were 14 million new cancer cases in 2012 and 8.8 million cancer-related deaths in 2015 globally. The increasing prevalence of genetic disorders in newborns and life-threatening diseases, such as cardiovascular diseases and cancer, across the globe is expected to be the major driver of the global gene therapy market in the upcoming years. In addition, the growing need for targeted treatment and increasing awareness and acceptance of personalized medicines among patients are likely to further trigger the global gene therapy industry in the future. However, the requirement of an individual case-by-case approach and high treatment cost might hamper the gene therapy market on a global scale in the estimated timeframe.

Global Gene Therapy Market

Based on the type, the gene therapy market is bifurcated into somatic cell gene therapy and germ cell gene therapy. The somatic cell segment holds the maximum share of the global gene therapy market. Based on application, the gene therapy market is classified into genetic disorders, cancer, cardiovascular diseases, and others. Genetic disorders are likely to hold a significant market share over the forecast time period.

By region, North America dominated the global gene therapy in 2017 market and is expected to remain the dominant region over the forecast time period as well. This can be attributed to the developed healthcare infrastructure, favorable government policies, and research activities across the region. The Asia Pacific is likely to register the fastest rate of growth in the gene therapy market in the upcoming years, owing to the low cost of clinical trials and large regional population, especially in India, China, and Japan. The Latin American gene therapy market is projected to grow moderately over the estimated time period. The Middle Eastern and African market is projected to experience noticeable growth in the years ahead.

Some key players of the gene therapy market include UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension Therapeutics, Voyager Therapeutics, Human Stem Cell Institute, Bristol Myer’s Squibb, and Chiesi Farmaceutici S.p.A., among others.

}